🇺🇸 FDA
Patent

US 11786488

Dosage forms and methods for enantiomerically enriched or pure bupropion

granted A61KA61K31/137A61P

Quick answer

US patent 11786488 (Dosage forms and methods for enantiomerically enriched or pure bupropion) held by AXSOME THERAPEUTICS, INC. expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
AXSOME THERAPEUTICS, INC.
Grant date
Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/137, A61P, A61P25/14, A61P25/28